Women with high levels of insulin-like growth factor 1 (IGF-1) may be at increased risk for breast cancer, according to results of a study that used both epidemiological techniques as well as genetic ...

Results from the ProtecT trial—the largest study to date investigating the link between circulating insulin-like growth factors (IGFs) and prostate cancer—convincingly refute a much-debated role for ...

November 26, 2008 — Results of a randomized trial have shown no benefit of treatment with insulinlike growth-factor type 1 (IGF-1) in slowing progression of disease, compared with placebo, among ...

In an industry often clouded by opaque sourcing and inconsistent quality, Peptide Hubs stands as a beacon of transparency. Every product in the new lineup undergoes a rigorous journey before it ...

Levels of the hormone increase with disease severity, a new study has found. Plasma levels of insulin-like growth factor 1 (IGF-1) could give clinicians a better understanding of whether a patient ...

Now UAB researchers, led by Guanlan Xu, Ph.D., and Shalev drilled down further into the mechanism underlying verapamil’s beneficial effect. In a paper published in Diabetes, they show that, in Type 1 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The PATHFNDR-2 trial enrolled adults with acromegaly who ...

Since its discovery over 50 years ago, the biological aspects of insulin-like growth factor-1 (IGF-1) have been determined to be extensive. Ranging from cell proliferation, cell differentiation and ...

Increased signaling of the insulin-like growth factor (IGF) system via alterations in expression levels of its components has been demonstrated in various tumor types. Numerous experimental studies ...

A molecular prognostic nomogram for resectable pancreatic cancer. Background: Hepatocellular carcinoma (HCC) is a vascular tumor, derived mainly by vascular endothelial growth factor (VEGF)-mediated ...

Seurat Therapeutics, Inc. (Seurat) announced today the publication of preclinical studies of its lead product candidate, intranasal insulin-like growth factor-1 (IGF-1), in a rat model of migraine ...